PLENARY SPEAKERS

ICONAN 2019 conference will gather high-profile Nanomedicine and Nanobiotechnology experts to deliver plenary speeches:

Prof. Simona Mura

Prof. Simona Mura

Institut Galien Paris-Sud, France

After a Master Degree in Chemistry and Pharmaceutical Technology at the University of Cagliari (Italy), Dr Mura has been awarded her PhD in Chemistry and Technology of Drug in 2009 at the same university working on the design and in vitro evaluation of novel vesicular systems for the topical delivery of drugs. In 2008 she joined the group of Prof. Elias Fattal (Galien Institute, UMR CNRS 8612) at the University Paris-Sud (France), as a post-doctoral research assistant to study the lung toxicity of biodegradable nanoparticles designed for pulmonary drug administration.

In 2011, she has been appointed Associate professor in the same University within the framework of the «CNRS-Higher Education chairs» program (Chaires d ‘excellence CNRS) and she has integrated the team of Patrick Couvreur. Since 2015 she is also regularly hosted as Visiting Associate professor at the University of Osaka (Japan). Her research focuses on the design of biomimetic drug delivery systems and the construction of in vitro and in vivo models for a relevant preclinical assessment of the therapeutic efficacy of nanomedicines. She is (co)author of 50 peer review articles in international journals, 4 book chapters and co-editor of 1 book. Dr Mura has also been appointed Junior member of the prestigious Institut Universitaire de France (IUF) in 2017.

Prof. Ernst Wagner

Prof. Ernst Wagner

LMU Munich, Germany

Ernst Wagner is full professor of Pharmaceutical Biotechnology at Ludwig-Maximilians-Universität (LMU) of Munich since 2001 and member of Center for Nanoscience (CeNS). He coordinates the area of ‘Biomedical Nanotechnologies’ of the Cluster of Excellence ‘Nanosystems Initiative Munich (NIM)’. Dr. Wagner received a Ph.D. in Organic Chemistry from the Technical University of Vienna. After a postdoctoral stay at the ETH in Zurich, he became group leader at the Institute of Molecular Pathology and at the Vienna University Biocenter, developing synthetic gene transfer systems. In parallel, 1992-2001 he was Director for Cancer Vaccines at Boehringer Ingelheim Austria, where he developed the first-in-world polymer-based clinical gene therapy study in 1994. 

Complete biography here

Talk title: Sequence-defined carriers for optimizing nucleic acid nanomedicines by chemical evolution

Prof. Andrew Owen

Prof. Andrew Owen

University of Liverpool, UK

Andrew Owen is Professor of Molecular and Clinical Pharmacology at the University of Liverpool, UK. He is Chair of the British Society for Nanomedicine, a fellow of the Royal Society of Biology, a fellow of the British Pharmacological Society, and a fellow of the Learned Society of Wales. His clinical and basic research focuses on understanding mechanisms that underpin inter-patient variability in pharmacokinetics and pharmacodynamics. A major emphasis has been to employ knowledge of these mechanisms to accelerate the translation of technologies to clinical applications for oral and long-acting drug delivery. His ongoing research portfolio is funded by NIH, USAID, EPSRC, EC and pharmaceutical and charitable agencies. He has published over 200 publications, is co-inventor of patents relating to drug delivery and is a co-founder of Tandem Nano Ltd (www.tandemnano.com) and PKTK (www.PKTK.co.uk). Professor Owen also co-leads the UK contribution to the European Nanomedicine Characterisation Laboratory (www.EUNCL.eu) and the modeling core for the Long-acting/Extended-release Antiretroviral resource Program (www.LEAPresources.org). He is also an Editor in Chief for the Journal of Interdisciplinary Nanomedicine (www.JOINjournal.com).

 

Talk title: Opportunities and challenges for long-acting drug delivery: the changing paradigm for chronic disease therapy

Dr. Cristianne Rijcken

Dr. Cristianne Rijcken

Chief Scientific Officer and a Founder of Cristal Therapeutics, The Netherlands

Dr. Cristianne Rijcken is Chief Scientific Officer and a Founder of Cristal Therapeutics. Dr. Rijcken’s PhD thesis provided a strong basis for Cristal Therapeutics and she was awarded multiple grants and prizes including the Simon Stevin Gezel Award in 2008 and the Knowledge for Growth Inspiring Young Scientist Award in 2014. She has authored over 30 scientific publications and is named on all Cristal Therapeutics’ patents and patent applications. In recognition of Dr Rijcken’s innovative approach, strength in translational research and her entrepreneurial attitude, she was awarded the Limburg Businesswoman of the Year in 2017. Cristianne is pharmacist by training and holds a PhD degree in Pharmaceutics from Utrecht University, The Netherlands.

Dr. Roy van Der Meel

Dr. Roy van Der Meel

Eindhoven University of Technology, The Netherlands

Roy van der Meel obtained his PhD at Utrecht University under direction of Gert Storm and Wim Hennink. He conducted postdoctoral research in the labs of Raymond Schiffelers at the University Medical Center Utrecht and Pieter Cullis at the University of British Columbia, funded by a Marie Skłodowska-Curie Action and a Veni grant from the Netherlands Organization for Scientific Research. Roy is currently appointed as Assistant Professor at the Eindhoven University of Technology’s Biomedical Engineering department where he heads the Precision Medicine group under direction of Willem Mulder. His group’s research is focused on developing nanotherapeutics to regulate the immune response in a highly precise manner.

Dr. Matthias Barz

Dr. Matthias Barz

AK Barz Lab, Johannes Gutenberg University Mainz, Germany

Dr. Matthias Barz was born in 1982 in Frankfurt Main, Germany. After finishing high school he studied chemistry at the Johannes Gutenberg-University Mainz (Germany) and Seoul National University (South Korea), received a diploma degree in chemistry in 2006 and a PhD in polymer chemistry from the Johannes Gutenberg-University Mainz (Germany) working under the supervision of Prof. R. Zentel. After finishing his PhD he worked in the laboratory of Dr. Maria J. Vicent at the CIPF in 2010 as a postdoctoral researcher. In 2011 he returned briefly to Mainz as a senior researcher before joining the group of Prof. T. Kirchhausen at Boston Children’s Hospital, Harvard Medical School (endocytosis of nanomedicines). In 2013 he became independent junior research group leader and started his habilitation at the Institute of Organic Chemistry at the Johannes Gutenberg-University Mainz (Germany). In the end of 2016 he received the venia legendi for organic chemistry and became lecturer at the JGU. He is currently head of the graduate center and member of the steering committee of the collaborative research center for nanoparticle based cancer immune therapy (CRC 1066) and member of an H2020 consortium (Click-It) and an ITN (PET-AlphaSy).

Prof. Dario Neri

Prof. Dario Neri

ETH Zürich, Switzerland

Dario Neri was born in Rome on 1 May 1963 but grew up in Siena (Italy). He studied Chemistry at the Scuola Normale Superiore of Pisa and earned a Ph.D. in Chemistry at the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor Kurt Wüthrich (Nobel Prize Chemistry 2002). After a post-doctoral research internship (1992-1996) at the Medical Research Council Centre in Cambridge (UK), under the supervision of Sir Gregory Winter (Nobel Prize Chemistry 2018), he became a professor at ETH Zürich in 1996.
Dario Neri is currently Full Professor of Biomacromolecules at the Department of Chemistry and Applied Biosciences, ETH Zürich. The research of the Neri group focuses on the engineering of therapeutic antibodies for the therapy of cancer and other angiogenesis-related disorders and on the development of DNA-encoded chemical libraries.
Dario Neri is a co-founder of Philogen (www.philogen.com<http://www.philogen.com/>), a Swiss-Italian biotech company which has brought various antibody products into multicenter clinical trials for the treatment of cancer and of chronic inflammatory conditions.

Dario Neri has published 400 articles in peer-reviewed scientific journals. He is the recipient of the ISOBM Abbott Prize 2000, of the Amgen-Dompe’ Biotec Award 2000, of the Mangia d’Oro 2001, of the Prous Award 2006 of the European Federation of Medicinal Chemistry, of the Robert-Wenner-Prize 2007 of the Swiss Cancer League, of the SWISS BRIDGE Award 2008, of the Prix Mentzer of the French Medicinal Chemistry Society in 2011, of the Phoenix Prize 2014 and of an ERC Advanced Grant in 2015.

Talk title: From encoded combinatorial libraries to targeted therapeutics

Prof. Paolo Decuzzi

Prof. Paolo Decuzzi

Italian Institute of Technology, Italy

Paolo Decuzzi is a senior researcher and director of the Laboratory of Nanotechnology for Precision Medicine at the Italian Institute of Technology in Genova – Italy. Dr. Decuzzi earned his M.Sc. degree in Mechanical Engineering from the Politecnico di Bari (Italy) in 1997 and his Ph.D. degree in Mechanical Engineering from the University of Naples – Federico II (Italy) in 2000, with a thesis on friction and adhesion at the nanoscale. In 2002, he was nominated Assistant Professor of Machine Design at the Politecnico di Bari and, in 2005, he became Associate Professor in the School of Medicine of the University ‘Magna Graecia’. There, he co-founded BioNEM – the laboratory of BioNanotechnology and Engineering for Medicine – one of the first nano-engineering laboratories built in a School of Medicine. In October 2007, he joined The University of Texas Health Science Center in Houston as an Associate Professor of Biomedical Engineering. In October 2010, he moved to the Houston Methodist Hospital where he served as a Professor of Biomedical Engineering till July 2015. There, he founded the Center for the Rational Design of Multifunctional Nanoconstructs, with the financial support of the Cancer Prevention and Research Center of Texas and the US National Cancer Institute; and served first as the co-chair of the Nanomedicine Department and then as the interim chair of the Translational Imaging Department. In July 2014, Dr. Decuzzi was awarded a 5-year European Research Council “Consolidator Grant” to design, synthesize and develop nanoconstructs for imaging and therapy in brain cancer.

Dr. Decuzzi has been visiting scientist at the Department of Theoretical and Applied Mechanics at the University of Michigan – Ann Arbor (1998, 1999 and 2001); and visiting professor at the Princeton Material Institute – Princeton (2003); the Heart and Lung Institute at the Ohio State University (2003 and 2004); the University of Texas Health Science Center (2006).

Dr. Decuzzi has published over 150 papers in international peer-reviewed journals, international conferences and book chapters. He holds over 5 patents in the field of Nanomedicine. He co-founded NEMB – NanoEngineering for Medicine and Biology – committee of the American Society for Mechanical Engineers and is involved in multiple dissemination activities to foster the collaboration between biomedical scientists and engineers. He serves on multiple NIH, NSF, ESF, and Italian Government study sections and his research activity is primarily supported by NIH, DOD, CPRIT in USA; ESF and ERC in EU.

Decuzzi’s lab mission is to

  1. rationally design polymeric nanoconstructs for multi-modal imaging and combination therapy in cancer, cardiovascular and neurological diseases;
  2. fabricate microfluidic chips for the rapid screening of novel molecular and nano-based therapeutic agents;
  3. develop multi-scale, hierarchical computational models for predicting the transport and therapeutic efficacy of nanoconstructs;
  4. organize dissemination activities at the interface between engineering and biomedical sciences; and
  5. promote the professional development of lab members in a highly multi-disciplinary environment.

 

Talk title: Tuning particle deformability in drug delivery systems

Dr. Bart Metselaar

Dr. Bart Metselaar

Enceladus Pharmaceuticals / RWTH Aachen University, Germany

My name is Josbert M. Metselaar, born in Rotterdam July 6th, 1971. I obtained an MSc degree in Pharmaceutical Sciences in 1995 and a PharmD degree in 1998, both at Utrecht University. During my study, I completed a research internship in pharmacology and PK/PD at the Dept of Pharmaceutics, University of Florida, US. In 1999 I started a Ph.D. at the Dept of Immunology and the Dept of Pharmaceutics in Utrecht where I studied novel targeted formulations of anti-inflammatory medicines.

After completing my Ph.D. in 2003 and a Post Doc fellowship in 2005, I decided to translate part of my accomplishments into investigational medicinal products by starting a company named Enceladus, with which I raised more than 6 million Euros funding over the years. With these investments and additional non-equity funding I successfully performed a series of preclinical and clinical development projects on three liposomal products, including 6 clinical trials.

In 2012 I took a part-time academic position in the group of Targeted Therapeutics at the University of Twente, where I worked on drug carrier design and formulation development in the field of advanced drug delivery for inflammation, atherosclerosis, and cancer. In 2015 I took a position at the Dept. of Experimental Molecular Imaging at the RWTH Aachen University Clinic in Germany, where I especially focus on translational aspects of nanomedicine for cancer treatment and diagnosis (imaging).

Besides my academic career, I have more than 12 years of experience in industrial drug product development, covering all pharmaceutical development aspects as well as preclinical and clinical studies. My relevant areas of expertise include formulation design and development for advanced drug delivery, quality control, nanomedicine pharmacokinetics, biodistribution and safety studies, and clinical study design and implementation.

Prof. Marianne Ashford

Prof. Marianne Ashford

Innovative Medicines Biotech Unit, AstraZeneca, UK

Marianne Ashford, Ph.D., is a Senior Principal Scientist in a global role in Advanced Drug Delivery, serving on the Pharmaceutical Sciences and Oncology Science Leadership Teams. Marianne is responsible for applying drug delivery approaches which enable the progression of innovative medicines and is working to enable novel targets through intracellular delivery of new modalities.

Marianne has been instrumental in introducing nanomedicines into the AstraZeneca portfolio. She has initiated several collaborations and the building of the internal capability in nanomedicines and drug targeting. Previously Marianne has led a Preformulation and Biopharmaceutics Group which was responsible for influencing candidate drug design from a product perspective. Marianne has also held project management roles leading pharmaceutical teams and influencing the global product strategy.

Marianne has published over 55 peer-reviewed papers, six book chapters and holds several patents. She has delivered invited talks, keynotes and plenaries in nanomedicine and advanced drug delivery worldwide. Marianne is an Honorary Professor at the University of Nottingham and serves on numerous academic and industrial scientific committees and advisory boards in the field of drug delivery. Marianne is passionate about using her scientific knowledge and experience to improve therapies for patients and applying drug delivery technologies which enable medicines of the future.

 

Prof. Lars Lindner

Prof. Lars Lindner

University Hospital of the Ludwig-Maximilians-Universitaet Munich, Germany

Lars Lindner is a medical oncologist having received his training as a medical doctor at the University of Göttingen, Germany, and the Ludwig-Maximilians-Universitaet Munich, Germany. He spent his final year of medical school at the Cornell Medical Center, the Memorial Sloan Kettering Cancer Center and the Mount Sinai Medical College, all New York City, USA, and the Stadtspital Triemli, Zurich, Switzerland. He conducted his Ph.D. studies with Prof. Eibl at the Max Planck Institute for Biophysical Chemistry in Göttingen, Germany, focusing on novel liposomal drug delivery technologies, and spent his Postdoctoral Fellowship at Erasmus Medical Center, Rotterdam, the Netherlands, at the Laboratory of Experimental Surgical Oncology with Prof. Dr. Alexander Eggermont. Today, he is a Professor of internal medicine, hematology, and oncology at the University Hospital of the Ludwig-Maximilians-Universitaet Munich, Germany. He is managing director of the Sarcoma Center SarKUM, one of Germany’s largest and leading centers dedicated to the diagnosis and treatment of cancer patients with all types of sarcomas, and the hyperthermia treatment center, one of the world’s largest and most renowned centers for regional deep hyperthermia in cancer patients. In addition, he supervises a research group dedicated to basic and applied research on a novel, liposomal drug delivery technologies.

He is the inventor of several patents and author/co-author of more than 100 scientific publications and various book chapters, with a strong focus on regional deep hyperthermia as a compassionate use with chemotherapeutic-based oncological treatment regimes, sarcoma as an oncological indication, as well as thermosensitive liposomal drug delivery technologies to enhance drug-based treatment regimes in various solid tumors. He is the co-inventor of parts of Thermosome’s TSL technology and conducted extensive basic research as well as in vitro and in vivo experiments with Thermosome’s TSL technology throughout his academic career.

Talk title: Heat mediated drug delivery with temperature sensitive liposomes – a synergistic approach.

Prof. Raymond Schiffelers

Prof. Raymond Schiffelers

University Medical Center Utrecht, The Netherlands

I obtained my Ph.D. degree from Erasmus University Medical Center Rotterdam, The Netherlands. My thesis focused on liposomal targeting of antimicrobial agents. From 2000-2011, I worked at the dept Pharmaceutics of Utrecht University working on polymers, micelles, and liposomes, loaded with small molecular weight drugs as well as biologicals, in pre-clinical disease models. Within this period, I spent 2002-2003 working for Intradigm Co. (USA) on formulations for in vivo targeting of siRNA. In 2010 I was awarded an ERC Consolidator grant to investigate extracellular vesicles for drug delivery. In 2011, I moved to University Medical Center Utrecht where I investigate natural and synthetic nanoparticles for drug delivery and diagnostics.

Currently, I am coordinating the H2020 project B-SMART on targeting RNA to the brain and am preparing to head the EXPERT consortium focused on mRNA delivery. In addition, I participate in several EU and national projects on nanomedicine.

Talk title: RNA delivery: between extracellular vesicles and lipid nanoparticles.

Dr. Maria Vicent

Dr. Maria Vicent

Centro Investigacion Principe Felipe, Spain

Dr. María J. Vicent received her Ph.D. degree in 2001 in chemistry on solid supports from University Jaume I Castellón after several scientific stays in Prof. Fréchet’s lab. at University California, Berkeley (USA). Then, she moved to more biomedically oriented research, initially with a Spanish company Instituto Biomar SA., and subsequently at the Centre for Polymer Therapeutics with Prof. R. Duncan after the award of a Marie Curie Postdoctoral Fellowship in 2002. In 2004, María joined Centro de Investigación Príncipe Felipe (CIPF) as research associate through a Marie Curie Reintegration contract and was promoted to her current position, head of Polymer Therapeutics Laboratory at CIPF, in 2006. Currently, she is the scientist responsible for the Screening Platform and also coordinates the Advanced Therapies Program at CIPF. She has been the coordinator of the Valencian Community Strategy on Innovative Medicines becoming one of the Specialist sites in the ERIC EU-OPENSCREEN.

Her research group focused on the development of novel nanopharmaceuticals for different therapeutic and diagnostic applications, in particular, Polymer Therapeutics for unmet clinical needs and has been funded by national and European grants (several acting as coordinator including an ERC Consolidator grant-MyNano and ERC-PoC-POLYIMMUNE) from academia as well as industry (funding »7M€). María received several prizes including the IVth and the IXth Idea awards, she has been elected as a member of American Institute for Medical and Biological Engineering (AIMBE) College of Fellows Class of 2019. María has co-authored >100 peer-reviewed papers (h index: 36; »5000 citations, google scholar) and 10 patents, 2 of them licensed to the pharmaceutical industry and a third one used as foundation of the spin-off company ‘Polypeptide Therapeutic Solutions SL’ in 2012. She was the Spanish President of the Spanish-Portuguese Chapter of the Controlled Release Society up to end 2013 and the chair of key conferences on the nanomedicine field such as, the International Symposium on Polymer Therapeutics: From Laboratory to Clinical Practice Or the Anual meeting CRS 2019. María is a member of the editorial board of the key journal in the field including Adv. Drug Deliv Rev, J. Control Rel., Nanomedicine: NBM, Polymer Chemistry, Biomaterial Sciences, Mol. Pharmaceutics or Adv Polym Sci. María has already supervised 10 Ph.D. students and 9 more are ongoing, many through different competitive grants.

More information at http://www.VicentResearchLab.com and http://www.cipf.es 

Talk title: Polypeptide-based Conjugates as Versatile Therapeutics

Prof. Giuseppe Battaglia

Prof. Giuseppe Battaglia

University College London, UK

Giuseppe, or as most people call him, Beppe, Battaglia is an EPSRC Established Career Fellow and 2018 ERCCoG investigator, the Chair in Molecular Bionics in the Department of Chemistry and Honorary Professor of Chemical Engineering at the Department of Chemical Engineering at the University College London (UCL). Beppe is part of the Institute of Physics of Living System at UCL and he is the director of the EPSRC/Jeol Centre for Liquid Phase Electron Microscopy. In 2019, Beppe was awarded a prestigious Catalan Institution for Research and Advanced Studies (ICREA) chair to join the Institute of Bioengineering of Catalunya (IBEC) part of the Barcelona Institute of Science and Technology. Beppe will divide his time between UCL and BIST for the next 5years.

Prior to joining UCL, Beppe held positions as Lecturer -2006, Senior Lecturer -2009 and Professor -2011 in the Departments of Materials Sci.Eng. (2006-2009) and Biomedical Science (2009-2013) at the University of Sheffield. Beppe has published over 100 research articles, reviews, and book chapters and he is named inventor in 10 patents. Beppes is co-founder and serves as Chief Scientific Officer of two startups, SomaServe ltd, and SomaNautix ltd. Beppe was awarded the 2009 HFSP Young Investigator Award jointly with Prof A. Engler from UCSD, the 2011 APS/IoP Polymer Physics Exchange Award Lecture, the 2011 GSK Emerging Scientist Award, 2011 ERC Starting Grant, the 2012 Award for special contribution to Polymer Therapeutics, the 2014 RSC Thomas Graham Award Lecture, 2015 SCI/RSC McBain Medal for Colloid Science and the 2016 Anhui 100 Foreign Talent Award.

Talk title: Phenotypic targeting via multiplexed and chemotactic polymersomes.

Dr. Alexander N. Zelikin

Dr. Alexander N. Zelikin

Aarhus University, Denmark

Dr. Alexander N. Zelikin earned a Ph.D. degree in Polymer Chemistry from Moscow State University (Russia) in 2003 and held research positions at MIT, Cornell University, and the University of Melbourne. In 2009, he joined the Department of Chemistry and the iNano Interdisciplinary Nanoscience Centre, Aarhus University, Denmark where he lectures Medicinal Chemistry. In 2009, Alex received an ERC Consolidator grant for the research on implantable biomaterials. His awards include the Lundbeck Fund Young Investigator award and the Danish Academy of Technical Sciences award for biomedical research.

His research interests include macromolecular drugs and prodrugs, antiviral therapies, enzyme prodrug therapies, biomaterials, as well as synthetic biology and nanozymes. He published 100+ peer-reviewed research articles.

Prof. Mauro Ferrari

Prof. Mauro Ferrari

Professor, Director, and Executive Vice President, University of St Thomas, Houston Texas USA

Dr. Mauro Ferrari is an Independent Director of Arrowhead Pharmaceuticals Inc. Dr. Ferrari has been the President and CEO of The Houston Methodist Hospital Research Institute (TMHRI), Executive Vice President of Houston Methodist Hospital and Senior Associate Dean of Weill Cornell Medical College in New York. He is also the President of The Alliance for NanoHealth. Dr. Ferrari is an internationally recognized expert in nanomedicine and biomedical nanotechnology. Prior to assuming leadership of TMHRI, Dr. Ferrari was Professor and Chairman of The Department of NanoMedicine and Biomedical Engineering at The University of Texas Health Science Center at Houston, Professor of Experimental Therapeutics at the MD Anderson Cancer Center, Adjunct Professor of Bioengineering at Rice University and Adjunct Professor of Biomedical Engineering at the University of Texas in Austin.

His previous academic appointments include tenured professorships at UC Berkeley and The Ohio State University. Ferrari’s qualifications to serve on the Board include his extensive training and experience in the fields of nanotechnology, biotechnology, and biomedical applications. Dr. Ferrari has significant technical training, several academic appointments, over 300 published articles, over 30 issued patents and is the recipient of most prestigious academic awards in nanomedicine and drug delivery technology. Additionally, Dr. Ferrari has extensive experience in developmental stage organizations having founded several startup companies.

Prof. Marcelle Machluf

Prof. Marcelle Machluf

Faculty of Biotechnology and Food Engineering, TECHNION, Israel

Marcelle Machluf is full professor and -dean of the Faculty of Biotechnology and Food Engineering at the Technion Haifa Israel. She also was the Deputy Executive Vice President for Research for the Pre-Clinical Research Authority and the head of the Interdisciplinary Biotechnology Program at the Technion. Marcelle Machluf holed a Ph.D. degree from the Faculty of Chemical Engineering the unit of Biotechnology, Ben Gurion University Bear Sheva, in Liposomes and polymer delivery for vaccines development. Prof Machluf had a post-doctoral fellowship of five years experience in drug delivery, gene therapy and tissue engineering in Harvard Medical School, Boston MA, US.  Professor Machluf laboratory focuses on developing scaffolds for tissue engineering of the heart, blood vessels, and pancreas. The focus is on natural isolated extracellular matrix (ECM) scaffolds, which are modulated injectable, microcapsule or other 3D platforms.  Prof Machluf has an Adjunct Professor position in the prestigious School of Material Science Engineering (NTU, Singapore as well as a laboratory and a leading tissue regenerative project of 15M$ sponsored by the government of Singapore. Her group, which consists of 12 Ph.D. students, 3 postdocs and 2-research assistants, also focuses on developing and engineering nano-drug and gene delivery platforms for cancer therapy.  Professor Machluf has published more than 80 papers (among which Nature Biotec, Nano Letters, Cancer Research, J of Controlled Release) and chapters in books and has 7 patents in national phase and 2 international approved ones in the field of drug delivery and tissue engineering. Prof Machluf is on the editorial board of several journals among which are Scientific Report Controlled release and Tissue Engineering and part of the Minerva Program Committee, under the Max-Planck Institute (Germany). She is currently the President of the Israeli controlled release society.

Prof Machluf has received also several scientific awards such as Alon Award for excellence in science, the Gutwirth Award for achievements in the gene therapy field, Recipient of the Hershel Rich Innovation Award, the Juludan Prize for Outstanding Research and holds the Cathedra of WD Irving & Adele Rosenberg career development chair as well as the Cathedra of Benno Gitter & Ilana Ben Ami Chair in Biotechnology. Her work in drug delivery was selected by the Israel Ministry of Science and Technology as one of Israel’s sixty most impactful scientists for developments in the field of advanced cancer therapies.  She was also chosen to light the torch for the 70th independent year of the state of Israel. Recently Lady Globes Magazine selected her as the Women of the Year (2018).

Prof. Thomas Bein

Prof. Thomas Bein

LMU Munich, Germany

Thomas Bein received his Ph.D. in Chemistry from the University of Hamburg (Germany) and the Catholic University Leuven (Belgium) in 1984. He continued his studies as Visiting Scientist at the DuPont Central Research and Development Department in Wilmington, DE (USA). From 1986 to 1991 he was Assistant Professor of Chemistry at the University of New Mexico in Albuquerque (USA). In 1991 he joined Purdue University (Indiana) as Associate Professor and was promoted to Full Professor of Chemistry in 1995. In 1999 he was appointed Chair of Physical Chemistry at the University of Munich (LMU), where he also served as Director of the Department of Chemistry.

He has recently won an ERC Advanced Grant entitled “Electroactive Donor-Acceptor Covalent Organic Frameworks”. Presently he is the Coordinator of the DFG Excellence Cluster “Nanosystems Initiative Munich (NIM)”, as well as Co-Coordinator of the newly funded Excellence Cluster “e-conversion”. Bibliographic data: Over 430 publications, over 26.000 citations, h=90 (WoS). Thomas Bein is a Highly Cited Researcher (Clarivate Analytics).

His current research interests cover the synthesis and physical properties of functional nanostructures, with an emphasis on porous materials for targeted drug delivery and nanostructured and molecular framework materials for energy conversion applications.

More plenary speakers and more information are coming soon.